Plasma glycooxidation protein products in type 2 diabetic patients with nephropathy

Diabetes/Metabolism Research and Reviews

Volumn 24, Issue 7, 2008, Pages 549-553

  Piwowar, Agnieszka ^a   Knapik Kordecka, Maria ^a   Szczecínska, Joanna ^a   Warwas, Maria ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

AGE; AOPP; Nephropathy; T2DM

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED OXIDATION PROTEIN PRODUCT; ALBUMIN; CREATININE;

ADULT; ALBUMIN BLOOD LEVEL; ALBUMINURIA; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DISEASE SEVERITY; FEMALE; FLUOROMETRY; GLYCATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; SPECTROPHOTOMETRY; URINALYSIS; AGED; BLOOD; MIDDLE AGED; OXIDATION REDUCTION REACTION; PHYSIOLOGY; URINE;

ADULT; AGED; ALBUMINURIA; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; MIDDLE AGED; OXIDATION-REDUCTION; OXIDATIVE STRESS;

EID: 58149142854     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.885     Document Type: Article

References (33)

1. Abou-Seif AM, Youssef AA. Evaluation of some biochemical changes in diabetic patients. Clin Chim Acta 2004; 346: 161-170.
2. Kalousova M, Zima T, Tesar V, Dusilova-Sulkova S, Skrha J. Advanced glycooxidation end products in chronic diseases - clinical chemistry and genetic background. Mutat Res 2005; 579: 37-46.
3. Bonnefont-Rousselot D. Glucose and reactive oxygen species. Curr Opin Clin Nutr Metab Care 2002; 5: 561-568.
4. Martin-Gallan P, Carrascosa A, Gussinye M, Dominguez C. Biomarkers of diabetes associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. Free Radic Biol Med 2003; 341: 563-574.
5. Kalousova M, Škrha J, Zima T. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res 2002; 51: 597-604.
6. Tsukahara H, Sekine K, Uchiyama M, et al. Formation of advanced glycosylation end products and oxidative stress in young patients with type 1 diabetes. Pediatr Res 2003; 54: 419-424.
7. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001; 44: 129-146.
8. Ulrich P, Cerami A. Protein glycation, diabetes, and aging. Recent Prog Horm Res 2001; 56: 1-21.
9. Kasper M, Funk RH. Age-related changes in cells and tissues due to advanced glycation end products (AGEs). Arch Gerontol Geriatr 2001; 32: 233-243.
10. Gugliucci A, Bendayan M. Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia 1996; 39: 149-160.
11. Münch G, Keiss R, Weis A, et al. Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem 1997; 35: 669-677.
12. Vlassara H, Striker G. Glycotoxins in the diet promote diabetes and diabetic complications. Curr Diab Rep 2007; 7: 235-241.
13. Tan AL, Forbes JM, Cooper ME. AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol 2007; 27: 130-143.
14. Witko-Sarsat V, Friedlander M, Nguyen-Khoa T, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304-1313.
15. Selmeci L, Székely M, Soós P, et al. Human blood plasma advanced oxidation protein products (AOPP) correlates with fibrinogen levels. Free Radic Res 2006; 40: 952-958.
16. Robertson RP, Harmon J, Tran POT, Poitout V. β-Cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes. Diabetes 2004; 53(Suppl. 1): S119-S124.
17. O'Connon AS, Schelling JR. Diabetes and the kidney. Am J Kidney Dis 2005; 46: 766-773.
18. Newman DD, Mattock MB, Dawnay AB, et al. Systematic review on urine albumin testing for early detection of diabetic complications.[in]. Health Technol Assess 2005; 9: xiii-x163.
19. Shumway JT, Gambert SR. Diabetic nephropathy - pathophysiology and management. Int Urol Nephrol 2002; 34: 257-264.
20. Schosinsky K, Vargas M, Esquinet A, Chavaria A. Simple spectrometric determination of urinary albumin by dye-binding with of bromophenol blue. Clin Chim Acta 1987; 33: 223-226.
21. Lehmann R, Schleichner E. Molecular mechanism of diabetic nephropathy. Clin Chim Acta 2000; 297: 135-144.
22. Van Dijk C, Berl T. Pathogenesis of diabetic nephropathy. Rev Endocr Metab Disord 2004; 5: 237-248.
23. Aso Y, Innukai T, Tayama K, Takemura Y. Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes. Acta Diabetol 2000; 37: 87-92.
24. Sharp PS, Rainbow S, Mukherjee S. Serum levels of low molecular weight advanced glycation end products in diabetic subjects. Diabet Med 2003; 20: 575-579.
25. Hirata K, Kubo K. Relationship between blood levels of N-carboxymethyl-lysine and pentosidine and the severity of microangiopathy in type 2 diabetes. Endocr J 2004; 51: 537-544.
26. Piwowar A, Knapik-Kordecka M, Warwas M. AOPP and its relations with selected markers of oxidative/antioxidative system in type 2 diabetes mellitus. Diabetes Res Clin Pract 2007; 77: 188-192.
27. Knapik-Kordecka M, Piwowar A, Warwas M. Oxidative-antioxidative balance disturbance and risk factors as well as vascular complications in patients with diabetes type 2 (polish text). Wiad Lek 2007; 60: 329-334.
28. Kalousova M, Sulkova S, Fialova L, et al. Glycooxidation and inflammation in chronic haemodialysis patients. Nephrol Dial Transplant 2003; 18: 2577-2581.
29. Selmeci L, Szekely M, Soos P, et al. Human blood plasma advanced oxidation protein products (AOPP) correlates with fibrinogen levels. Free Radic Res 2006; 40: 952-958.
30. Zilin S, Naifeng L, Bicheng L, Jiping W. The determination of AGE-peptides by flow injection assay, a practical marker of diabetic nephropathy. Clin Chim Acta 2001; 313: 69-75.
31. Henle T. AGEs in food: do they play a role in uremia? Kidney Int Suppl 2003; 84: S145-S147.
32. Saito A, Takeda T, Sato K, et al. Significance of proximal tubular metabolism of advanced glycation end products in kidney diseases. Ann N Y Acad Sci 2005; 1043: 637-643.
33. Shi XY, Hou FF, Niu HX, et al. Advanced oxidation protein products promote inflammation in diabetic kidney through activation of renal nicotinamide adenine dinucleotide phosphate oxidase. Endocrinology 2008; 149: 1829-1839.